ArticleBMC cardiovascular disorders2025
Ablation by three-dimensional electroanatomical mapping versus anti-arrhythmic drug therapy: a cost-utility analysis in the treatment of idiopathic ventricular arrhythmias.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo assess the cost-utility of ablation guided by three-dimensional electroanatomical mapping (3DEAM) with antiarrhythmic drug (AAD) therapy in the management of patients with idiopathic ventricular arrhythmias (IVA) at a highly specialized cardiovascular center in Peru.
methodsA cost-utility economic evaluation was conducted in a public institution involving patients diagnosed with IVAs between 2017 and 2022. The analysis included projections adjusted according to life expectancy. Cost analysis was performed from the payer's perspective (public health insurance) using the macro-cost estimation methodology and applying a 9.6% discount rate. Utility values were derived from the SF-36 questionnaire, facilitating the calculation of average quality-adjusted life years (QALYs) for each group. Cost-utility analysis was executed by determining the Average Cost-Utility Ratio (ACUR) and the Incremental Cost-Utility Ratio (ICUR) against the cost-effectiveness threshold set for Peru.
resultsThe study included 52 patients with IVAs, with 34 undergoing 3DEAM ablation and 18 receiving AAD therapy. The recurrence rate (14.7% vs. 50%, p = 0.010) and complication/adverse event rate (0% vs. 22.2%, p = 0.011) were lower in the 3DEAM ablation group. Over a four-year time horizon, 3DEAM ablation resulted in higher average costs ($7,234.81 vs. $2,136.51), average QALYs (3.30 vs. 2.98), and ACUR ($2,187.26 vs. $716.31) compared to AAD therapy. The calculated ICUR was $15,684.78, which was below the cost-effectiveness threshold for Peru. Extending the analysis to align with life expectancy projections showed that average QALYs were significantly higher in the 3DEAM group (34.25 vs. 14.83) and with a lower ACUR ($230.94 vs. $646.01) and more favorable economic outcomes.
conclusionThe 3DEAM ablation strategy can be considered cost-utility intervention for treating IVAs in our region. These results are in line with published data on cost-effectiveness of 3DEAM ablations of IVA in developed countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.